Status:
COMPLETED
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liragluti...
Eligibility Criteria
Inclusion
- Subjects diagnosed with type 2 diabetes mellitus and treated with either diet or single oral drug therapy
- Diet treated subjects: 7.5% \< HbA1c \< 10%
- Single oral drug therapy subjects: 7.0% \< HbA1c \< 9.5%
- Body Mass Index (BMI): max 40 kg/m\^2
Exclusion
- Subjects treated with thiazolidinediones or insulin
- Subjects with any serious medical conditions
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT00154401
Start Date
January 1 2005
End Date
October 1 2005
Last Update
January 25 2017
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Aalborg, Denmark, 9000
2
Novo Nordisk Investigational Site
Århus C, Denmark, 8000
3
Novo Nordisk Investigational Site
Copenhagen, Denmark, 2400
4
Novo Nordisk Investigational Site
Hellerup, Denmark, 2900